Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

How CRISPR and AI Destroy the World Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste.

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR Therapeutics AG (CRSP) 10-day simple moving average is 41.52. CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...